summit trial tirzepatide results Effects of on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the In the SUMMIT trial, researchers

This ensures the clinical rationale for therapy is documented and supports consistent adjudication

This led to its approval by the FDA in the USA the same year under the trade name Ozempic. The medication was administered via injections for weight loss

Take action today by calling New Rochelle medical weight loss expert, David Lans, D.O

Stubborn Fat Deposits: Even after substantial weight loss, some fat pockets may remain in areas like the abdomen, thighs, or arms

According to the Summary of Product Characteristics (SmPC), the most commonly reported adverse effects include: Nausea and vomiting (very common) particularly during dose escalation Diarrhoea or constipation (very common) affecting bowel regularity Abdominal pain and discomfort (common) often mild to moderate Reduced appetite (very common) contributing to weight loss Dyspepsia (common) indigestion or heartburn Injection site reactions (common) such as redness or irritation Fatigue (common) tiredness or lack of energy These gastrointestinal symptoms typically diminish over time as the body adjusts to the medication